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Abstract
Background: GATA4 and FOG2 proteins are required for normal cardiac development in mice.
It has been proposed that GATA4/FOG2 transcription complex exercises its function through gene
activation as well as repression; however, targets of GATA4/FOG2 action in the heart remain
elusive.
Results: Here we report identification of the Lhx9 gene as a direct target of the GATA4/FOG2
complex. We demonstrate that the developing mouse heart normally expresses truncated
isoforms of Lhx9 – Lhx9α and Lhx9β, and not the Lhx9-HD isoform that encodes a protein with an
intact homeodomain. At E9.5 Lhx9α/β expression is prominent in the epicardial primordium,
septum transversum while Lhx9-HD is absent from this tissue; in the E11.5 heart LHX9α/β-positive
cells are restricted to the epicardial mesothelium. Thereafter in the control hearts Lhx9α/β
epicardial expression is promptly down-regulated; in contrast, mouse mutants with Fog2 gene loss
fail to repress Lhx9α/β expression. Chromatin immunoprecipitation from the E11.5 hearts
demonstrated that Lhx9 is a direct target for GATA4 and FOG2. In transient transfection studies
the expression driven by the cis-regulatory regions of Lhx9 was repressed by FOG2 in the presence
of intact GATA4, but not the GATA4ki mutant that is impaired in its ability to bind FOG2.
Conclusion: In summary, the Lhx9 gene represents the first direct target of the GATA4/FOG2
repressor complex in cardiac development.
Background
Unlike many developing organs that remain dormant
until the time of birth, a properly functioning embryonic
heart is essential for embryo survival. Hence, defects in
cardiac function are a common cause for embryonic
lethality. Gene targeting in mice revealed multiple genes
that are required for cardiac development and function;
however, the interplay between these genes often remains
a mystery. This is especially true for genes encoding for
transcription factors which are expressed in a dynamic
fashion in various cellular compartments that constitute
the developing heart.
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Genome Informatics) is prominently expressed in multi-
ple cell types that constitute the embryonic heart [1]. To
examine the function for FOG2 in cardiac development
gene-targeted mice have been generated [2]. Fog2-/- (null)
embryos die at mid-gestation (~E13.5) with a cardiac
defect characterized by an atrial septal defect, thin ven-
tricular myocardium, common atrioventricular (AV)
canal and the Tetralogy of Fallot malformation. Of partic-
ular additional interest is the finding that the develop-
ment of cardiac vasculature was blocked in Fog2-/- mice.
Despite the apparently normal formation of an intact epi-
cardial layer and expression of epicardium-specific genes
in Fog2 null mutants, markers of cardiac vessel develop-
ment (ICAM-2 and KDR) are not detected, indicative of
failure to activate their expression and/or to initiate the
epithelial to mesenchymal transformation of epicardial
cells [2,3]. These results are particularly insightful with
respect to KDR, since KDR (FLK1, VEGFR2), the major
receptor for VEGF (vascular endothelial growth factor), is
an important marker of vascular cells and is absolutely
essential for vascular development (e.g. [4], see [5] for a
review).
Although gene targeting revealed the requirement for
FOG2 in multiple aspects of cardiac development, the
specific genetic program (or programs) downstream of
FOG2 remained unknown. Research by us and others
established that multi-type zinc-finger proteins of the
FOG family (FOG1, FOG2, xFOG and dUSH) control bio-
logical activities of GATA transcription factors (for review,
see [6,7]). Based on the results from the hematopoietic
system it has been suggested that FOG proteins serve as
co-factors for GATA family members by forming a GATA/
FOG complex on specific GATA sites. Indeed, differen-
tially regulated genes have been identified for GATA1-
FOG1 complex vs. GATA1 alone in blood development
(e.g. [8]. Furthermore, these studies demonstrated that
FOG1 could stimulate or inhibit GATA1 activity depend-
ing on cell and promoter context [9]. For example, FOG1
stimulates GATA1 activity on the p45 NF-E2 gene pro-
moter, which is active in erythroid cells and megakaryo-
cytes [10]; however, it represses GATA1 activity on the
erythroid-specific Eklf and transferrin receptor II promot-
ers, as well as on a synthetic GATA1-dependent promoter
[11,12]
Earlier studies aimed at the similar characterization of the
GATA4-FOG2 relationship with respect to cardiac devel-
opment relied on transient transfection assays with well-
characterized Anf, Bnp and α-Mhc promoters that contain
GATA sites [13,14]. However, these genes are normally
expressed in mutant Fog2 null or Gata4ki/ki hearts (the
V217G Gata4 mutation [15] which specifically cripples
the interaction between GATA4 and FOG proteins) argu-
ing against the essential role for GATA4/FOG2 complex in
their regulation [2,15,16]. Hence, transcriptional targets
of GATA4/FOG2 complex in the heart are currently
unknown.
The cardiac Gata4ki/ki phenotype showed numerous simi-
larities to the Fog2 null heart underscoring the role for
GATA4/FOG2 protein complex in cardiac gene regulation
[15]. However, the mode of GATA4/FOG2 action, as a
repressor or activator, remains unclear and necessitates
identification of its downstream targets. In order to iden-
tify the targets of GATA4/FOG2 action in the mammalian
heart we performed several Affymetrix microarray com-
parisons of gene expression in normal and mutant E13.5
hearts. As many groups have identified the regions in FOG
proteins that mediate their function as GATA co-repres-
sors [17-22], we expected that gene up-regulation (de-
repression) should be, at least partially, responsible for
causing cardiac syndrome in the GATA4/FOG2 mutants.
Here we describe one of the targets of GATA4/FOG2 com-
plex in its transcriptional repressor role, Lhx9 gene. LHX9
belongs to the family of the LIM-HD (LIM-homeodo-
main) proteins. The roles for the majority of LIM-HD
encoding genes have been mostly defined in the context
of nervous system development where they act to specify
neuronal identities of post-mitotic neurons (reviewed in
[23]). LIM-HD genes act in a context-dependent fashion,
cooperating with other factors to establish enormous
diversity of the nervous system [24]. The function for
LHX9 was proposed in the development of the nervous
system as this gene is prominently expressed in the
motoneurons of the spinal cord and in the developing
brain [25-28]. Despite this prominent neuronal expres-
sion pattern, knockout of Lhx9 in mice did not affect ani-
mal viability or neuronal development probably
reflecting a redundancy of Lhx9 and its close structural rel-
ative, Lhx2 [29]; unexpectedly, the knockout revealed a
requirement for Lxh9 in early gonad formation [29]. Our
studies demonstrate that GATA4/FOG2 transcription
complex regulates Lhx9 cardiac expression and suggest
that the role for Lhx9 in the development of the heart
should be evaluated.
Results
Cardiac expression of the Lhx9 gene splicing isoforms
In order to identify the targets of GATA4/FOG2 action in
mammalian heart development we performed an Affyme-
trix microarray comparison of gene expression in normal
and Fog2 null E13.5 hearts. The microarray profiling
yielded surprisingly few genes that were differentially
(~2.5 times up- or down-regulated) expressed in the
mutant samples vs. controls (Additional File 1 and data
not shown). Importantly, the probe set corresponding toPage 2 of 19
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as was expected.
One of the probe sets differentially represented in the con-
trol vs. Fog2 mutant RNA sample corresponded to the
Lhx9 gene (~3 times; Additional File 1) encoding the
LHX9 protein that belongs to the family of the LIM-HD
(LIM-homeodomain) transcription factors [23]. The
major research interest of this laboratory is in the tran-
scriptional regulation of cardiac development; hence we
decided to pursue the FOG2-Lhx9 connection. To cor-
rectly evaluate the microarray data it was critical to iden-
tify the actual mRNA species corresponding to the
microarray oligonucleotide probe set. The NCBI database
predicts three different mouse isoforms of Lhx9 mRNA;
two of these isoforms have been described previously,
while the third isoform has not been characterized. Origi-
nally identified transcript 3 encodes a 397 amino acid (aa)
long protein with intact homeodomain (HD) that is com-
petent to bind DNA [26,27]; this isoform is further
referred to as Lhx9-HD. A previously described isoform,
Lhx9α, encodes a 330 aa protein with truncated HD and a
different C terminus [30]; finally, the uncharacterized
transcript (variant 2) would encode a 321 aa protein that
has a different N-terminus in addition to a truncated HD
(Fig 1A, B). We will refer to the un-characterized isoform
as Lhx9β.
Alternative splicing isoforms of Lhx9Figure 1
Alternative splicing isoforms of Lhx9. A. Splicing isoforms of the mouse Lhx9 gene as predicted by the NCBI and Ensembl 
databases and (B) the proteins they encode. (I). Transcript variant 3 (NM_001042577; ENSMUST00000112026) encodes for a 
397 amino acid (aa) long protein with intact homeodomain (HD); (II). Transcript variant 1 (NM_001025565; 
ENSMUST00000019374) encodes for a 330aa protein LHX9α with a truncated HD and a different C terminus; (III) Transcript 
variant 2 (NM_010714; ENSMUST00000112030) is the uncharacterized transcript and would encode for a 321aa protein 
LHX9β that has a different N-terminus in addition to a truncated HD. Black boxes represent coding exons; white boxes show 
untranslated regions; blue and purple filled boxes represent LIM domains 1 and 2; red fill shows HD; the sizes for all exons 
(bps) are shown for each isoform. The Ensembl annotation predicts much longer 3'-untranslated regions for transcripts 1 (II) 
and 2 (III); these, however, were not detected previously [30] and could not be confirmed by us experimentally or by a 
BLASTN search against the EST database (not shown).Page 3 of 19
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using S35-labeled isoform-specific RNA probes detects
Lhx9α expression in the developing E13.5 heart, while the
full-length HD-encoding Lhx9-HD is not detected [30]. To
corroborate and extend this data we designed the primers
that discriminate between all three isoforms of Lhx9 and
performed real-time PCR analysis. By real time RT-PCR we
have determined that the major Lhx9 isoform expressed in
the developing heart at E13.5 corresponds to Lhx9α, while
Lhx9β transcript is expressed at a somewhat lower level
(Fig 2A). Cardiac expression of Lhx9 is under strict devel-
opmental control: qRT-PCR analysis of total heart RNA
demonstrated that combined Lhx9 expression corre-
sponding to both expressed isoforms (Lhx9α+β) is down-
regulated between E11.5 and E14.5 approximately 7-fold
(Fig 2B); during the same time period Fog2 gene expres-
sion is increasing (Fig 2C).
We also confirmed that a full-length isoform (Lhx9-HD) is
scarcely detectable in the embryonic heart even when
measured by a highly sensitive real time PCR assay. The
cardiac expression level of Lhx9-HD is ~30 times (at
E11.5; not shown) and ~50 times (at E13.5; Fig 2D) lower
than that of Lhx9α/β; this data is in agreement with the
previous work [30]. In contrast and as a positive control
we detected Lhx9-HD using the same primer pair as
robustly expressed in the E11.5 embryonic hind limb
where its levels were ~33 times higher than in the E11.5
heart (Fig 2E); in the hind limb Lhx9-HD expression was
only slightly lower (~3.3 times) than Lhx9α/β expression
(Fig 2F) (see also Fig 5 for in situ hybridization analysis).
Quantitative analysis of Lhx9 gene expression in the control and Fog2 null heartsFigure 2
Quantitative analysis of Lhx9 gene expression in the control and Fog2 null hearts. A. Agarose gel electrophoresis 
showing RT-PCR products corresponding to the Lhx9α and Lhx9β isoforms of the Lhx9 gene expressed in the E11.5 tissues. 
The products corresponding to the cardiac tissue (lanes 1 and 5) were isolated and sequenced. Relative cardiac expression of 
the α(2.6) and β(1.0) Lhx9 isoforms in the wild-type sample was determined by the real time PCR. (B-C). Lhx9α/β is downreg-
ulated (~7-fold) while Fog2 is upregulated in the wild-type E9.5–E14.5 heart as demonstrated by the real-time PCR analysis of 
the pan-cardiac Lhx9α/β (B) and Fog2 (C) expression. Lhx9α/β is not expressed in the E9.5 embryonic heart. (D). A compara-
tive analysis of Lhx9 gene expression in the control and Fog2 mutant E13.5 hearts using Lhx9-HD and Lhx9α/β isoform-specific 
primers. The Lhx9 expression for both isoforms is normalized to the Gapdh gene expression level; the fold changes (y axis) are 
shown; relative expression of Lhx9-HD is normalized to be 1.0. (E). A comparative analysis of the Lhx9-HD isoform expression 
in the E11.5 hearts and hind limbs. The Lhx9 expression is normalized to the Gapdh gene expression level; the fold changes (y 
axis) are shown; relative expression of Lhx9-HD in the heart is normalized to be 1.0. (F). A comparative analysis of Lhx9 gene 
expression in the E11.5 hind limb using Lhx9-HD and Lhx9α/β isoform-specific primers; relative expression of Lhx9-HD is nor-
malized to be 1.0.Page 4 of 19
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Based on the microarray data analysis the combined value
of the probe sets corresponding to Lhx9α+β was ~3 times
higher in the E13.5 Fog2-null sample (Additional File 1).
Real time PCR analysis confirmed the increase in Lhx9α/β
expression in the mutant. The up-regulation is already sig-
nificant at E11.5 (~4.5 excess vs. control) and becomes
even more dramatic (6.4 times) at E13.5 (Fig 3A). Analysis
with isoform-specific primers revealed that the overall
increase in the mutant is derived mostly from the up-reg-
ulation of the Lhx9β isoform (6.1x), although expression
of Lhx9α in the Fog2 mutant heart is also doubled (2.3x)
(Fig 3B). The expression of the isoform encoding the full-
length protein, Lhx9-HD, is also induced in the Fog2
mutant heart, but its level remains negligibly low (Fig
2D). In contrast, the expression of the Lhx2 homologue
does not change in the mutant (Fig 3B).
To further compare the expression of Lhx9 in the control
and Fog2 mutant cardiac samples we performed in situ
whole-mount hybridization experiments using an anti-
Lhx9 RNA probe that detects both isoforms (α/β). In the
wild-type E11.5 heart the ventricles, the atrioventricular
groove and the outflow tract are weakly positive for
Lhx9α/β expression, while in the Fog2 null heart Lhx9α/β
expression is strongly enhanced (Fig 3C–D). By E12.5 and
especially by E13.5 Lhx9α/β expression appears almost
extinguished in the control heart, while the Fog2 mutant
sample is strongly positive for Lhx9α/β (Fig 3E–H). These
results correlate well with the real-time PCR data (Fig 2B
and Fig 3A–B). The non-cardiac expression of Lhx9α/β
(e.g. spinal cord, limb buds and testes) remains compara-
ble in the control and mutant embryos (Fig 5 and Addi-
tional File 2A, B; also data not shown).
LHX9α/β is localized to the epicardium in the fetal heart
To establish the identity of cardiac cells that express
Lhx9α/β we sectioned the stained hearts following the
RNA in situ hybridization. As Lhx9α/β expression in the
wild-type heart is low, we analyzed the mutant samples.
We observed that Lhx9α/β expression is restricted to the
outermost layer of the heart (not shown). To ensure that
this staining is not a result of a poor probe penetration, we
sectioned the wild-type and mutant E11.5 hearts and per-
formed immunofluorescent analysis with an anti-LHX9
antibody. Among several antibodies we have tested (data
not shown) only one [31] was suitable for the immun-
ofluorescence analysis of embryonic samples. In addition
to LHX9α/β this anti-LHX2/9 antibody recognizes both
LHX2 and LHX9-HD; however, RNA species encoding
both of these proteins are absent (i.e. Lhx9-HD (Fig 2D, E
and [30]; Lhx2 [32]) from the E11.5 embryonic heart.
The antibody demonstrated strong and specific staining in
all embryonic regions that were previously reported to
have strong Lhx2/Lhx9 expression (e.g. gonads; Additional
File 2C). In the heart the protein expression correlated
well with the Lhx9α+β in situ staining pattern. LHX9α/β
protein expression was detected in atria, ventricles and
outflow tract; the expression was enhanced in the atriov-
entricular groove (Fig 4). Again, cells located in the outer-
most cardiac layer were the only cells that stained strongly
positive for LHX9α/β. These cells (Fig 4A) stained negative
for the pan-myocardial marker, TNNT2 at all times exam-
ined (Fig 4B–C) and data not shown).
To label the cells in the epicardial region at this early stage
in epicardial development we used an antibody specific
for the endothelial integral membrane glycoprotein endo-
glin (ENG) [33] that recognizes epicardial cells that are
already committed to the endothelial lineage both in the
control and in Fog2 mutant hearts [2]. At E11.5 the epicar-
dial layer containing LHX9α/β-positive cells is still nega-
tive for ENG, while at E12.5 stage this endothelial marker
starts to detect some (but not all) ventricular cells in the
epicardial and sub-epicardial layer. We concluded that in
the embryonic heart LHX9 α/β proteins are temporarily
expressed in the developing epicardial cell layer. Although
the majority of the LHX9-positive cells are confined to the
epicardium, a weaker immunoreactivity is detectable in
the myocardium (Fig 4) suggesting that a low level expres-
sion of LHX9α/β could be present in these cells.
Lhx9α/β and Lhx2, but not Lhx9-HD are expressed in the 
proepicardium
Lineage studies in chick embryos have demonstrated that
epicardium is derived from the extra-cardiac source, the
proepicardium [34-38]; in mice these cells are derived (at
least partially, see also [39]) from the septum transversum
[40-42]. The epicardial progenitor cell cysts are formed in
the proepicardial serosa at E9.5–E10.5 and cover the myo-
cardium with a single layer of flat cells by E10.5–11.5
[43,44]. By performing an in situ hybridization for Lhx9α/
β with E9.5 embryos we noted that Lhx9α/β is promi-
nently expressed in the septum transversum in both the
wild-type and Fog2 mutant embryos (Fig 5A, top panels).
Expression of the Lhx9 homologue, Lhx2, in the septum
transversum (STM) has been previously reported [45];
however, we noted that the authors in their analysis used
a probe that corresponds to the whole-length Lhx2 cDNA
(NM_010710; nucleotides 460–1750). A sequence com-
parison revealed two large regions of almost complete
identity between the Lhx2 probe sequence and Lhx9;
hence, we believe the authors [45] could not discriminate
between Lhx2 and Lhx9 in their in situ assay. To distin-
guish between these homologues we designed an Lhx2
probe that is limited to the most 5'-region of the Lhx2Page 5 of 19
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The analysis of Lhx9 expression in the control and mutant heartsFigure 3
The analysis of Lhx9 expression in the control and mutant hearts. (A-B). Lhx9 gene expression is up-regulated in the 
Fog2 mutant hearts. (A). A comparative real-time PCR analysis of the total (Lhx9α/β) expression in the E11.5 and E13.5 control 
and Fog2 mutant hearts. (B). A comparative analysis of Lhx9 and Lhx2 gene expression in E13.5 control and Fog2 mutant hearts; 
Lhx9 expression is examined with α- and β isoform-specific primers. Lhx genes' expression is normalized to the Gapdh gene 
expression level; the fold changes (y axis) are shown; relative expression in the wild-type sample is normalized to be 1.0. (C-
H). Whole-mount staining of the E11.5 (C-D), E12.5 (E-F) and E13.5 (G-H) hearts with an anti-Lhx9α/β RNA probe. Both 
ventral (C, E, G) and dorsal (D, F, H) views are shown; the wild-type sample is always on the left. In the wild-type E11.5 heart 
(C-D) ventricles, the atrioventricular groove (arrow) and the outflow tract are weakly positive for Lhx9 expression, while in the 
Fog2 null heart, Lhx9 expression is strongly enhanced. By E12.5 (E-F) and especially by E13.5 (G-H) Lhx9 expression appears 
almost extinguished in the control heart, while the Fog2 mutant sample remains strongly positive for Lhx9 expression. The 
scale bar is 200 μM.
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LHX9α/β protein expression is specific to the epicardium of the heartFigure 4
LHX9α/β protein expression is specific to the epicardium of the heart. (A-C) Immunofluorescence analysis of 
LHX9α/β expression in frozen sections of E11.5 heart. (A) LHX9 (red; A and C) does not co-localize with cardiac muscle 
marker TNNT2 (cardiac troponin T) (green; B-C). LHX9-positive cells are localized to the outmost cardiac layer (arrows). Scale 
bar 50 μM. (D-L). LHX9α/β-positive cells (red; D, G, J, F, I, L) are localized to the outermost cardiac layer (arrows) in E11.5 
(D-F) and E12.5 control (G-I) and Fog2 mutant (J-L) cardiac sections. The endothelial marker ENG (endoglin) (green; E-F; H-
I; K-L) labels the epicardial cells already committed to the endothelial lineage beginning at E12.5 (arrowheads). Scale Bar: 50 
μM. Control sections required longer time exposures to detect the weaker LHX9 staining in the wild-type hearts.
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(A) Lhx9 α/β and Lhx2, but not Lhx9-HD are expressed in the septum transversum in mice at E9.5Figure 5
(A) Lhx9 α/β and Lhx2, but not Lhx9-HD are expressed in the septum transversum in mice at E9.5. Whole-mount 
in situ hybridization with anti-Lhx9α/β (top panels) and Lhx2 (middle panels) RNA probes detect a strong Lhx9α/β expression in 
septum transversum both in the control (left panels, arrow) and the Fog2-/- embryo (right panels, arrow); an Lhx9-HD RNA probe 
does not show the expression of this isoform in the septum transversum (bottom panels); hindlimb bud expression is indicated 
by an arrowhead. The higher magnification of STM expression for Lhx9α/β is shown in insets (top panels). (B) The myocardial 
Fog2 does not suppress Lhx9α/β expression in the heart. Whole-mount staining of the E14.5 hearts with the anti-Lhx9α/β RNA 
probe. The wild-type sample is on the left and the αMhc-Fog2/Fog2-/- heart is on the right. At this stage Lhx9α/β expression is 
extinguished in the wild-type heart (left) (also Fig. 2B) while the Fog2 mutant sample with the myocardial-restricted expression 
of Fog2 (right) remains strongly positive for Lhx9α/β expression.
BMC Developmental Biology 2008, 8:67 http://www.biomedcentral.com/1471-213X/8/67sequence (NM_010710; nucleotides 42 to 488) and has
no homology to Lhx9; we also generated an in situ probe
that is specific for Lhx9-HD. We detected an Lhx2 tran-
script in the STM (Fig 5A, middle panels). In contrast, the
transcript corresponding to the full-length Lhx9-HD could
not be detected in the STM (Fig 5A, bottom panels); this
rules out the transient role for the Lhx9-HD transcript in
the STM. We detected no STM up-regulation of either Lhx2
or Lhx9α/β in the absence of Fog2; if anything, it appears
that both Lhx9 α/β and Lhx2 could be expressed slightly
lower in the STM of Fog2 mutants (e.g. Fig 5A, insets in top
panels).
We have previously shown that transgenic expression of
Fog2 (restricted to the myocardium with an Mhc pro-
moter) extends the life of the otherwise Fog2-null
embryos; however this rescue by myocardial-derived Fog2
is incomplete [2,46]. If Lhx9α/β expression is mostly con-
fined to the epicardium and directly regulated there by a
FOG2 protein, myocardially-driven FOG2 should not be
able to repress Lhx9α/β expression back to its original low
level. To test this we examined Lhx9α/β expression in the
control and 'rescued' αMhc-FOG2/Fog2-/- hearts at E14.5.
Rescued hearts preserved a high level of Lhx9α/β com-
pared to the control indirectly attesting to the fact that
myocardial Fog2 is not primarily responsible for regulat-
ing Lhx9α/β expression (Fig 5B). This finding prompted us
to examine whether FOG2 could be directly regulating
Lhx9α/β expression as described below.
Lhx9 is a direct target of GATA4/FOG2 repression 
complex in the heart
The loss of GATA4/FOG2 interaction leads to an over-
expression (de-repression) of Lhx9α/β cardiac expression.
Based on the inability of myocardially-restricted FOG2 to
down-regulate ectopic epicardial Lhx9α/β expression (Fig
5B), we hypothesized that the Lhx9 gene could be a direct
target of GATA4-FOG2 mediated repression. To demon-
strate that the repression of the Lhx9 gene requires binding
of the GATA4/FOG2 protein complex to the Lhx9 cis-reg-
ulatory elements we inspected the Lhx9 genomic locus
using ECR (evolutionary conserved region) browser [47]
(Additional File 3A). As both Lhx9α and Lhx9β are
expressed in the heart we examined the conserved regions
corresponding to both isoforms. We limited our analysis
to the ~5 kb region upstream of the Lhx9β transcription
start site; this 5 kb region is delimited by the un-character-
ized ORF (2310009B15Rik in the mouse; C1ORF53 in the
human genome) (Fig 6A and Additional File 3A). We
identified two evolutionary conserved GATA sites within
the annotated ECRs (Fig 6A, B and Additional File 3A);
one GATA site (-521) is present within the promoter
region corresponding to the Lhx9α while the other site (-
4441) is located upstream of both isoforms (Fig 6A). To
examine the GATA4/FOG2 complex binding to these two
elements in vivo, we performed a chromatin immunopre-
cipitation (ChIP) assay from E11.5 embryonic hearts. This
time point was chosen since at E11.5 cardiac expression of
Lhx9 is still present in the normal heart and is responsive
to Fog2 expression: Lhx9α/β expression is strongly
enhanced in the absence of Fog2 (Figs 2D and 3A–D). We
demonstrated that either the α GATA4 or α FOG2 anti-
body specifically pulls down DNA containing conserved
GATA sites indicating the binding of the GATA4/FOG2
complex at E11.5 (Fig 6C). As a negative control we have
randomly chosen an internal region (within the Lhx9
gene) that contains two perfect GATA elements (AGATAG;
Fig 6A and Additional File 3B). This region tested negative
in the GATA and FOG2 ChIP assays (Fig 6D); we have also
confirmed the specificity for primers and the FOG2 anti-
body by a quantitative PCR analysis of ChIP reactions (Fig
6D). We conclude that in the E11.5 heart GATA4/FOG2
complex directly binds Lhx9 cis-regulatory regions.
GATA4 and FOG2 cooperate to inhibit Lhx9 promoters
To confirm that the GATA-harboring DNA sequences
upstream of the Lhx9 transcriptional start sites are essen-
tial for GATA4/FOG2-dependent regulation we per-
formed luciferase reporter assays. Lhx9 regulatory
sequences containing ECRs with ChIPed GATA sites (-
4968/-4301 and -1121/+1; Fig 6A) were isolated and used
to generate luciferase reporter constructs. The reporter
constructs were transiently transfected into the 293 HEK
cells along with the GATA4 and FOG2 expression vectors.
We also generated a GATA4ki expression vector (encoding
for the V217G mutation in GATA4 that does not interact
with FOG2 [15]). The wild-type GATA4 cooperates with
FOG2 to repress Lhx9 promoter-driven luciferase expres-
sion while the mutant GATA4ki version of GATA4 is
severely impaired in this repression assay (Fig 6E, F). A
luciferase construct containing a GAAA mutation in the (-
521) GATA element was not co-repressed by a joint
GATA4/FOG2 action (Fig 6E). We conclude that the
repression of Lhx9 gene expression in the developing heart
requires the presence of the functional GATA4/FOG2 pro-
tein complex.
LHX9α and LHX9β interact with ISL1, but not CITED2
We established that the loss of GATA4/FOG2 interaction
leads to over-expression of Lhx9α/β in the murine heart.
One of the consequences of the excessive LHX9α/β
expression could be the 'trapping' of cardiac LHX factors
with their interacting proteins into non-functional LHX9
α/β-containing complexes as has been previously pro-
posed [30]. To further test this idea we probed the interac-
tions between LHX9α and cardiac proteins that have been
reported to interact with the LIM-HD factors, namely ISL1
[48,49] and CITED2/MRG1 [50]. The eukariotic expres-
sion vector encoding the epitope-tagged version of LHX9α
was co-transfected with the epitope-tagged ISL1α, ISL1βPage 9 of 19
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Lhx9 gene is a direct target of the GATA4/FOG2 transcription complexFigur  6
Lhx9 gene is a direct target of the GATA4/FOG2 transcription complex. (A). A map of the mouse Lhx9 genomic locus. Exons are shown as blue and yellow boxes; the 
blue boxes correspond to the protein coding regions while yellow bars depict the UTRs. Both Lhx9 and 2310009B15Rik (an uncharacterized ORF flanking the Lhx9 locus) are 
oriented 5'-3' left-to-right. The Lhx9 introns are shown as thin blue lines. The DNA sequences corresponding to the intergenic space for all three isoforms are shown in green. 
The positions of the evolutionary conserved GATA sites are shown as vertical red bars and their distances with respect to the translation start sites +1(ATG) are indicated; the 
non-functional GATA sites are situated 3' from the start sites and ("+2x") are shown as black bars. The arrowheads are indicating the sequences amplified in the ChIP assay (see 
Materials and Methods for primer sequences). The horizontal red lines correspond to the DNA fragments used to generate the luciferase reporter constructs. (B). Alignement 
of the conserved reverse GATA sites (emboldened) in five genomes; the distance is shown from the first nucleotide (T) of the GATA site relative to the ATG codone of the 
respective isoform: β (top) and α (bottom). (C). Immunoprecipitations of the cross-linked chromatin from E11.5 hearts were performed with antibodies against FOG2, GATA4, 
RNA polymerase II or with normal IgG. Following DNA purification, samples were subjected to PCR with primers designed for the regions of the Lhx9 gene that contain GATA 
sites or the Gapdh promoter as a control; the PCR products were visualized on ethidium bromide gels. The PCR products were consistently observed with the total input chro-
matin aliquot before the immunoprecipitation step (not shown). The figure is a representative of four experiments performed.(D) The ChIP reactions corresponding to the α 
GATA4 and α IgG (same as in (C)) were subjected to PCR with primers designed to amplify the internal region of Lhx9 with two perfect consensus GATA sites 
(2xAGATAG;Additional File 2B) and were analyzed directly by the ethidium bromide gel (top panel). α FOG2 and α IgG ChIPs (same as in (C) were subjected to real-time PCR 
either with primers corresponding to the regulatory GATA-containing sequences or with internal primers. Primers corresponding to the two regulatory sequences amplify the 
α FOG2 ChIP reaction 70 and 18 times more efficiently than the α IgG reaction (left panel); they also amplify the α FOG2 reaction ~18 and 8 more efficiently than internal prim-
ers (middle panel); the amplification efficiency for the three sets of primers with respect to the control IgG reaction is close to 1 (right panel). The Y axis is showing the fold 
change. (E-F) GATA4 and FOG2 cooperate to inhibit Lhx9 promoters. (E) Luciferase reporter assays using Lhx9-luciferase reporters pGL3_Lhx9_1121 (black bars) or 
pGL3_Lhx9_1121Gm (white bar) or (F) pGL3_SV40_Lhx9_938 (black bars) in HEK 293-T cells with GATA4, FOG2 and GATA4ki expression vectors. pGL3_Lhx9_1121Gm con-
tains a GAAA sequence instead of the wild-type GATA sequence in position -521; the differences between the control and the mutant plasmid are not significant except for the 
transfection shown (the white bar). **p < 0.01, paired t-test vs control.
BMC Developmental Biology 2008, 8:67 http://www.biomedcentral.com/1471-213X/8/67or CITED2 into HEK293 cells and protein interactions
were tested by immunoprecipitation-western (IP-West-
ern) analysis. We detected the interactions between
LHX9α and both iso-forms of ISl1, but not between
LHX9α and CITED2 (Fig 7). This demonstrates the ability
of the LHX9 isoform lacking HD to form a complex with
other LIM-HD factors, such as ISL1.
ISL1 and LHX2/LHX9 are co-expressed in the developing 
liver, but not epicardium or septum transversum
Previous lineage studies in chick embryos have demon-
strated that the smooth muscle of the coronary vessels
derives from the proepicardium; similarly, in the mouse
these cells are derived from the septum transversum.
LHX9α/β is prominently expressed in the STM at E9.5 and
in the epicardium starting at E11.5 (Figs 3 and 5). Recent
lineage tracing analysis in Isl1-Cre mice has demonstrated
that the progeny of Isl1-expressing cells contributes to
endothelial and vascular smooth muscle lineages, specifi-
cally the smooth muscle of coronary vasculature [51]. As
our IP-Western analysis showed that LHX9α can interact
with ISL1 (Fig 7) we sought to determine whether LHX2/
LHX9α/β and ISL1 were co-expressed in the epicardium or
septum transversum and performed double-fluorescence
labeling experiments in E10.5 embryos. We were unable
to co-localize ISL1 to LHX9 α/β-positive epicardial cells
(Fig 8, top panels; arrows); this data is in agreement with
the reported absence of ISL1 expression in the epicardium
[51]. Similarly, cells in the septum transversum that
stained positive with an anti-LHX2/LHX9 antibody were
also ISL1-negative (Fig 8, top panels; arrowheads); we,
however, detected a subset of cells that co-express ISL1
and LHX2/9 in the developing liver (Fig 8, bottom panels;
arrowheads). Expression of Lhx9 in the developing liver
has been previously reported [27].
Discussion
Recent evidence suggests that different splicing isoforms
of the same transcription factor may have competing/
opposing as well as unrelated roles in cellular differentia-
tion (e.g., [52-54]). We have demonstrated that GATA4/
FOG2 transcription complex is essential for the repression
of Lhx9 gene transcription in cardiac development; we
have also determined that the Lhx9 isoform encoding for
the protein with intact homeodomain is not present in the
embryonic heart, while both α and β isoforms encoding a
truncated homeodomain are expressed. This differential
expression of Lhx9 isoforms suggests that truncated LHX9
LHX9α can interact with ISL1 isoforms, but not with CITED2Figure 7
LHX9α can interact with ISL1 isoforms, but not with CITED2. Immunoprecipitation-Western analysis of protein 
interactions in the extracts of HEK293 cells transfected with DNA constructs encoding HA-tagged LHX9α and MAB21L2 
(unrelated protein used as a negative control) and FLAG-tagged ISL1α, ISL1β and CITED2, as indicated.Page 11 of 19
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length LHX9 molecule. This assertion is supported by the
previously reported observation that LHX9 isoforms do
not directly compete with each other and instead function
in different pathways during neuronal differentiation
[55].
One of the objectives of this study was to identify the
downstream targets of GATA4/FOG2 regulation in vari-
ous sub-compartments of the developing heart and to
understand how the mis-regulation of these targets con-
tributes to severe cardiac defects in Fog2-null and Gata4ki/
ki embryos. We have now determined that Lhx9α/β is a tar-
get of GATA4/FOG2 repression, with wild-type hearts
down-regulating Lhx9α/β epicardial expression starting at
least on E11.5, while hearts deficient in FOG2 fail to do so
(Fig 3). The inability of the Fog2-null heart to down-regu-
late Lhx9α/β expression may be a contributing factor in
the constellation of the cardiac abnormalities caused by
Fog2 deficiency [2]. Although this study mostly focused
on the Fog2 mutants, real-time PCR analysis with the
E12.5 Gata4ki/ki hearts [15] also revealed a significant,
albeit weaker, up-regulation of the Lhx9α/β gene expres-
sion in this mutant (~3 times; data not shown). This more
modest up-regulation in the Gata4ki mutant could be due
to partial compensation by the other Gata family mem-
ber, Gata6, that is expressed in the developing heart.
We also demonstrated here that Lhx9α/β expression is ini-
tiated in the septum transversum (Fig 5) and that these are
the epicardial cells that continue expressing LHX9α/β in
E11.5 hearts and downregulate this expression shortly
thereafter. Further experiments will confirm whether
LHX9-positive epicardial cells are direct descendants of
the septum transversum cells. The requirement to down-
regulate Lhx9 expression is no longer satisfied in the epi-
cardium of the Fog2-null mutant hearts (Fig 3). We pro-
pose that abnormally high level of Lhx9 gene expression
that is characteristic of an earlier stage in epicardial cell
development is likely to be a contributing factor in the
impaired differentiation of the epicardially derived cells
in the Fog2 mutant embryos [2].
ISL1 is co-expressed with LHX2/9 proteins in the liver primordiumFigure 8
ISL1 is co-expressed with LHX2/9 proteins in the liver primordium. Immunofluorescence analysis of ISL1 and LHX2/
9 expression in frozen sections of the E10.5 embryos. LHX2/9 staining (red) does not co-localize with ISL1 (green) in the epi-
cardium (arrows) or septum transversum (arrowheads); the proteins are co-expressed in the liver primordium. The bottom 
panels are higher magnifications of the areas within white rectangles (top).Page 12 of 19
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roles of the two evolutionary conserved GATA sites in
Lhx9 gene cis-regulatory elements. Since DNA complexes
were precipitating with either anti-GATA4 or anti-FOG2
antibodies, this assay demonstrated that in the E11.5
heart these sites are occupied by the GATA4/FOG2 com-
plex rather than GATA4 alone. We could no longer detect
GATA4/FOG2 complex binding to these sites in the E14.5
hearts (not shown) suggesting that Lhx9 repression at this
later stage of cardiac development is likely to be GATA4/
FOG2-independent. In agreement with the ChiP data,
luciferase reporter assays confirmed the cooperative
repression by GATA4 and FOG2 (Fig 6E, F). Although
GATA sites have been previously identified in the proxi-
mal promoters of Anf, Bnp and α-Mhc genes, these genes'
expression is not affected by the GATA4/FOG2 interaction
loss. It is possible that other transcription factors regulat-
ing Lhx9 expression ensure the selectivity of GATA4/FOG2
binding; however, computer analysis of ECRs harboring
GATA sites did not reveal sequence conservation for any
other transcription factors in these regions. Lhx9 gene
expression is restricted to a limited number of tissues dur-
ing development and is likely to be tightly regulated (e.g.
[26,27,31]). Transcriptional regulation of Lhx9 is not well
understood and the crosstalk between the (yet unknown)
activators of Lhx9 expression and its repressors, GATA4/
FOG2, remains to be elucidated. In this respect we also
cannot exclude the contribution of an indirect regulation
mechanism where GATA4/FOG2 would normally activate
a yet unknown repressor X of Lhx9 transcription; Fog2 loss
in this case will result in down-regulation of X and de-
repression of Lhx9. In summary, although our ChIPs as
well as transient transfection data argues in favor of a
direct repression mechanism, it is possible that, once
other trans-acting factors governing Lhx9 regulation are
uncovered, they will be also deregulated in the Fog2
knockout.
We have previously shown that transgenic expression of
Fog2 restricted to the myocardium with αMhc promoter
extends the life of the otherwise Fog2-null embryos; how-
ever this rescue by myocardial-derived Fog2 is incomplete
[2,46]. In this respect, increased level of Lhx9 expression
still persists in the E14.5 hearts of the 'rescued' αMhc-
Fog2/Fog2-/-mutants (Fig 5B) indirectly attesting to the fact
that myocardial Fog2 is not responsible for regulating
Lhx9α/β expression. It is likely that the inability to down-
regulate Lhx9 in the epicardium is, at least partially,
responsible for the incomplete rescue in the αMhc-Fog2/
Fog2-/- mutants. Importantly, in a sensitive qRT-PCR the
level of Lhx9 expression in αMhc-Fog2/Fog2-/- hearts was
slightly reduced (not shown) suggesting that a low level
myocardial Lhx9/LHX9 expression is present and control-
led by GATA4/FOG2.
Loss of GATA4/FOG2 interaction has a profound early
effect on testis differentiation [46]; similarly, the Lhx9
gene is expressed in the developing gonads and Lhx9 gene
targeting that removes two exons encoding for the LIM
domains results in an early gonadal defect [29]. However,
in contrast to the situation in cardiac development, we do
not observe an up-regulation of Lhx9 gene expression in
the gonads of GATA4/FOG2 mutants (e.g., Additional File
2) suggesting that GATA4 and FOG2 do not control Lhx9
in this tissue.
Currently, the function of LIM-HD factors in cardiac
development (with the notable exception of ISL1) is not
well understood. Computer analysis of gene expression
database (as well as our own microarray analysis, data not
shown) shows that Lhx6 is the only other member of the
Lhx family that is expressed in the developing heart in the
amount comparable to Lhx9α/β; no cardiac defect for
Lhx6 loss of function has been reported [56].
Our data confirms and extends the previous observation
that Lhx9 splicing isoforms are expressed in a tissue-spe-
cific manner [30]. We also demonstrated that these trun-
cated Lhx9 transcripts lead to the expression of the
protein; this is an important confirmation since an
appearance of an RNA encoding for a regulatory factor
does not always correlate with protein accumulation (e.g.
Myf5 RNA and not the protein are expressed in neurons
[57]). It was proposed that Lhx9α encodes for a protein
with a truncated HD that can compete with LHX9 (or
other LIM-HD factors) for limited amounts of nuclear
CLIM cofactors like Ldb1 [55]; Ldb1 knockout animals do
not develop heart anlage [58]. CLIM cofactors can dimer-
ize and interact with two LIM-HD proteins at the same
time ([48,59]; reviewed in [60]). In addition to the simple
sequestration of Ldb1, the adjustment of stoichiometry
between various CLIM-LHX complexes can involve differ-
ential degradation of some, but not other complexes
[61,62]. Finally, one of the consequences of the excessive
LHX9α/β-Ldb1 complex formation could be 'trapping' of
cardiac LHX factors with their interacting proteins into
non-functional LHX9 α/β-containing complexes. Our IP-
Western analysis demonstrated that both LHX9α and
LHXβ could interact with other LIM-HD proteins such as
ISL1 (Fig 7), suggesting that LHX9 α/β could function in
mammalian cells as part of the multi-protein complexes.
The ISL1 protein, however, is unlikely to serve as a partner
for LHX9α/β in the epicardium or septum transversum as
cells expressing LHX2/9 in these tissues do not express
ISL1 (Fig 8).
In summary, our data suggest that the function of the
LHX9α/β protein during the proepicardial development
should be evaluated. This function maybe masked by
other Lhx family members or by unrelated compensatoryPage 13 of 19
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mals [29]. We also provide evidence that GATA4/FOG2
regulate Lhx9 gene expression directly through binding to
the evolutionary conserved GATA sites in the Lhx9 regula-
tory regions. The loss of GATA4/FOG2 interaction leads to
de-repression of the LHX9α/β expression in epicardial
cells; this abnormally high expression may account for
some of the cardiac malformations observed in the
Gata4ki/ki and Fog2 null mutants.
Conclusion
LHX9 belongs to the family of the LIM-HD (LIM-homeo-
domain) transcription factors. We have now determined
that the developing mouse heart normally expresses trun-
cated isoforms of Lhx9 – Lhx9α and Lhx9β. Whereas, the
expression of the Lhx9 isoform that encodes a protein
with an intact homeodomain is extremely low. At E9.5
Lhx9α/β expression is prominent in the epicardial primor-
dium, septum transversum; in the E11.5 heart LHX9-pos-
itive cells are localized to the epicardial mesothelium.
Thereafter in the control hearts Lhx9α/β epicardial expres-
sion is promptly down-regulated; in contrast, mouse
mutants with Fog2 gene loss fail to repress Lhx9α/β expres-
sion. Chromatin immunoprecipitation from the E11.5
hearts established the roles of the two evolutionary con-
served GATA sites in Lhx9 gene cis-regulatory elements. In
transient transfection studies the expression driven by the
cis-regulatory regions of Lhx9 was repressed by FOG2 in
the presence of intact GATA4, but not the GATA4ki mutant
that is impaired in its ability to bind FOG2. This study
identifies the first direct target for the GATA4/FOG2
repressor complex in the heart, Lhx9α/β.
Methods
Mouse strains and genotyping
Previously described Fog2+/- [2] and Gataki/+ [15] animals
were bred onto a pure C57Bl/6 background (a kind gift of
Dr. Eva Eicher, Jackson laboratory); αMhc-Fog2 animals
have been previously described [2,46]. Mice were geno-
typed by PCR using genomic DNA prepared from tail
snips. Fog2- null and wild-type alleles were distinguished




knock-in allele was detected as described previously [63]
by using primers GkiF TGCGGAAGGAGGGGATTCAAAC
and GkiR TCTGAGAGAACTGAGGGGGTTAGC. The pres-
ence of the αMhc-Fog2 transgene was determined by using
primers FP7 AGCGAGCGGAACCTGCAAG and FP9
TGTAGTTACAGACCGTGCA. All animal protocols have
been approved by the Dartmouth Animal Care and Use
Committee.
Microarray analysis
The total RNA from control and mutant (Fog2 null) E13.5
hearts was applied to Affymetrix microarray (Dartmouth
Genomic and Microarray laboratory); microarray data
was analyzed using the Gene Traffic (Iobion Informatics)
program.
Plasmids
pCS2+Gata4 and pCS2+Fog2 were previously described
[1]. To generate the pCS2+ Gata4ki mutant vector we intro-
duced the V217G mutation [15] by PCR using the follow-
ing primers: GCAGAGAGTGTGGCAATTGTGG (forward)
and CCACAATTGCCACACTCTCTGC (reverse).
pCS2+HA_Lhx9α. The full-length cDNA (993 bps)
encoding for the LHX9α isoform was generated from the
total cDNA prepared from E11.5 embryonic hearts using
the First Strand cDNA Synthesis Kit (Invitrogen). The PCR
fragment corresponding to the Lhx9a cDNA was generated
with the following primers: Lhx9α-FL_BamHI-F GGATC-
CCAATGGAAATAGTGGGGTGCCGAGCC and reverse
Lhx9α-FL-XhoI-R 5'-CTCGAGTAAGGGAATTT-
TCAAACGTCGGGAT. An insert was isolated by the
BamHI/XhoI digest and cloned into the pCS2+ vector
containing a HA tag (unpublished).
pCMV5a-Isl1α_FLAG and pCMV5a-Isl1β_FLAG plas-
mids were generated essentially as described above for
pCS2+HA_Lhx9α. PCR fragments corresponding to the
full-length Isl1α (1050 bp) or Isl1β (981 bp) cDNAs were
generated using the following primers Isl1_FL_BamHI_F
5'-GGATCCATGGGAGACATGGGCGATCC and reverse
Isl1_FL_BglII_R 5'-AGATCTTGATGCCTCAATAGGACT-
GGCTA; inserts corresponding to both isoforms were
excised with BamHI/BglII and cloned into a pCMV5a vec-
tor containing the C-terminal FLAG tag (Sigma).
pCMV5a-Cited2_FLAG was generated using a commer-
cially available plasmid (IMAGE clone 6415181; Open
Biosystems) as a template. A PCR fragment corresponding
to the full length Cited2 cDNA (810 bps) was obtained
with the following primers: Cited2-fl-BamHIF 5'-GGATC-
CATGGCAGACCATATGATGGCCATGAA and reverse
Cited2-fl-BglII-R 5'-AGATCTTGAACAGCTGACTCTGCT-
GGGCTGC; an insert was excised with BamHI/BglII and
cloned into pCMV5a.
pGL3_lhx9_1121 and pGL3_lhx9_1121Gm: The pro-
moter region (bps -1121 to -1 from the ATG codon of the
Lhx9α isoform) was isolated by PCR using genomic DNA
from CJ7 ES cells as a template. The following primers
were used: Lhx9_1121_KpnI-F GGTACCTTCACTTTGGT-
GGACGTCTCAGAGC (forward; a KpnI site is underlined)
and Lhx9_1121_NcoI-R CCATGGAAACACACGCCT-
GGGGCTCTCAGTT (reverse; a NcoI site is underlined). APage 14 of 19
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(Stratagene); KpnI/NcoI fragment containing the Lhx9
gene fragment was isolated and inserted into pGL3_Basic
vector (Promega) containing the luciferase reporter gene.
The mutant version of this promoter, 1121Gm, disrupted a
GATA site positioned at -521 upstream from the ATG
codone. The following primers were used to insert a muta-
tion: CTCCTACTAAATTTTCAAAAATGG (forward) and
CCATTTTTGAAAATTTAGTAGGAG (reverse); the TATC/
GATA site was replaced with the TTTC/GAAA sequence
(the altered sequence is underlined).
pGL3_SV40_lhx9_938: The enhancer region from -4968
to -4031 bp upstream of the ATG codon of the Lhx9β iso-
form was isolated by PCR essentially as described above.
The following primers were used: Lhx9_938_KpnI-F
GGTACCTCCATATGGCCAAGTCAATGTGA (forward; a
KpnI site is underlined) and Lhx9_938_NcoI-R CCAT-
GGTGAGCAGCAGCTTCCTGTTACTG (reverse; a NcoI
site is underlined). A PCR-generated fragment was intro-
duced into the pGL3_SV40 vector (Promega) containing
the luciferase reporter gene and the minimal SV40 pro-
moter.
The PCR fragments incorporated into DNA constructs
were verified by sequencing.
Total RNA extraction
Hearts (both ventricles and atria) were dissected from the
embryos and preserved in RNAlater (Ambion) until fur-
ther use. Hearts were disrupted by forcing the tissue
through a 26 gauge needle. Total RNA was prepared using
RNAeasy columns (Qiagen) according to the manufac-
turer's protocol. On average 1.5–2 μg of total RNA was
obtained from one E13.5 heart. RNA concentration was
determined by measuring absorbance at 260 nm; RNA
was stored at -80°C. Hind limb RNA was prepared follow-
ing essentially the same protocol, except that no shred-
ding of the tissue was necessary.
Quantitative Real Time RT-PCR
cDNA was prepared from 1–2 μgs of total cardiac RNA
with a First Strand cDNA synthesis kit (Invitrogen). Real-
time PCR was performed using a PCR SYBR Green I Kit
(Applied Biosystems) according to the manufacturer's
instructions in a 7500 Fast Real-Time PCR system
machine and a standard amplification protocol was estab-
lished for each gene. Calibration curves were generated
essentially as described before [64]. Values from at least
three independent experiments were compared; standard
deviation was calculated using Excel (Microsoft) applica-
tion.
The following primers were used for detection of Fog2 and
Lhx9 isoforms (See table 1).
Whole-mount in situ hybridization
The 504 bps Lhx9α/β probe corresponds to the 3'-untrans-
lated region of mouse Lhx9 RNA, +1146 to +1650 from
the ATG codone [30]. The probe region was amplified by
PCR using total cardiac E11.5 cDNA as a template with the
following primers: lhx9-1146-F GAGTGAGACATAAGT-
GTCATT (forward) and the lhx9-1650-R AATGTTTGCAT-
CAAATAAAATG (reverse). The 517 bps Lhx9-HD probe
corresponds to the + 1054 to +1571 from the ATG codone
of the isoform encoding for the HD-containing protein
(NM_001042577; [30] of Lhx9; the region was amplified
using the primers: lhx9-1054-F: CTCTCACTCCACCCG-
GCACTG and lhx9-1571-R: AGGAATATAAT-
TCGCCCATCGTAAT. Finally, the 466 bps Lhx2 probe
corresponded to the 5'-region (-425 to +21 from the ATG
codone) of Lhx2 (NM_010710); the primers used were
lhx2-425F: CACCTAGCTGTTCCTGGGTGAAC and lhx2-
21R: CCGACAGACTGTGGAACAGCATC. The PCR frag-
ments were cloned into the pSC-A vector (Stratagene) and
the digoxigenin-labelled RNA probes were generated
according to standard procedures [65]. In situ hybridiza-
tion and staining were performed as previously described
[2]. For each embryonic (E) time point at least two inde-
pendent experiments were done. Stained hearts or
embryos were re-fixed in 4% paraformaldehyde, washed
and kept in PBS. Images were acquired, processed and
mounted as previously described [66].
Chromatin Immunoprecipitation (ChIP)
For ChIP experiment hearts were dissected out in ice-cold
PBS; eighteen E11.5 or three E14.5 mouse hearts were
pooled. Tissue was chopped with a sharp razor blade and
Table 1: 
Primer forward 5'♦ 3' reverse 5'♦ 3' Accession number size
Fog2_ CGCCTTTGTGGTGGACTTTGACT GCTTCTCGTTGCCTCCCACTACA NM_011766 250
Gapdh GCTCACTGGCATGGCCTTCCGTG CGGAAGAGTGGGAAGAGACA NM_001001303 200
Lhx9-HD ACAAATTTGGTCTGCAAGATGTATT AGGAATATAATTCGCCCATCGTAAT NM_001042577 171
Lhx9α/β CAGAAGACCAAACGGATGCGAAC TAGGGAATTTTCAAACGTCGGGATGTT NM_001025565 198
Lhx9α ATGGAAATAGTGGGGTGCCGAGCC GTCTACGGCCAGCAGATAGTACCT NM_001025565 264
Lhx9β ATGCTGAACGGCACCACTCTAGAGG GTCTACGGCCAGCAGATAGTACCT NM_010714. 237
Lhx2 ACCACCAGCTTCGGACAATGA GCCCGTGTTTTCCTGCCGTAA NM_010710 172Page 15 of 19
(page number not for citation purposes)
BMC Developmental Biology 2008, 8:67 http://www.biomedcentral.com/1471-213X/8/67fixed in a freshly prepared 1% paraformaldehyde. Chro-
matin extraction and immunoprecipitations were per-
formed using an EZ ChIP assay kit (Upstate) according to
manufacturer's protocol. Chromatin was shared 6 × 10 sec
using the sonicator (MODEL 250, Branson) at 40% duty
cycle. Shared chromatin was pulled down either with the
goat anti-mouse GATA4 or goat anti-mouse FOG2 anti-
body (both from Santa Cruz); the control anti-mouse
RNA polymerase II, clone CTD4H8 antibody (Upstate); or
the control mouse IgG (Upstate). PCR products were
recovered by PCR Purification Kit (QIAGEN) PCRs were
done with Hotstart Taq DNA polymerase set (Qiagen)
using initial denaturation 95°C for 10 min (to activate
Tag polymerase) followed by 30 cycles of denaturation
(94°C; 20 sec), annealing (55°C; 30 sec) and extension
(72°C; 30 sec) with the final extension at 72°C for 5 min.
The following PCR primers were used to amplify the
regions of Lhx9 or Gapdh genes (See table 2).
PCR products were recovered from agarose gels and their
nucleotide sequences were confirmed.
Cell Culture and Transient Transfection Assays
Cells
293T HEK cells were maintained in DMEM media (Medi-
atech) with 10% newborn calf serum (NCS) and antibiot-
ics (DMEM/NCS).
Transfection
Transient transfections were performed using a standard
HBS × CaCl2 protocol [67]. 0.1–0.3 μg of Luciferase
reporter plasmids and 0.1–0.3 μg Renila plasmids were
combined with 2–3 μg of GATA4/GATA4ki or FOG2
expressing plasmids or 2–3 μg of a balancer plasmid. Cells
from one confluent well of a 6-well plate were used; cells
were incubated with the precipitate overnight and the
media was replaced with a fresh aliquot of DMEM/NCS
the next morning.
Luciferase Dual Reporter assay
Cells were lysed 48 hours post-transfection as recom-
mended by the Luciferase Dual Reporter Assay protocol
(Promega). After lysis the cells were centrifugated at max-
imal speed, the supernatant was diluted 10 times and used
immediately for measuring the luciferase activity; activity
of the firefly luciferase was normalised to the Renilla
reporter activity. Each experiment was repeated at least
three times. Each value was compared to control (reporter
vectors in the presence of the balancer plasmid) in each
experiment and values from three independent experi-
ments were analyzed; the final graph was built using
Microsoft Excel application (Microsoft).
Immunofluorescence Analysis
Embryos were fixed in 4% paraformaldehyde in PBS for 2
h (hours), washed with PBS for 4 h in a cold room using
several changes of PBS. Fixed embryos were soaked in
30% sucrose in PBS overnight at 4°C, positioned and fro-
zen in the OCT (Fisher Scientific) and kept at -80°C until
further use. 10 μM sections of the frozen embryos were cut
on the cryostat (Leica) and lifted on the Superfrost slides
pre-treated with the Vectabond (Vector). For the immun-
odetection of the LHX9 protein, slides were blocked/per-
meabilized in PBS containing 5% Carnation non-fat milk
and 0.1% Triton X-100 (Fisher) for 1 h at RT. Blocked
slides were reacted with the rabbit anti-LH2A/B antibody
(a kind gift from Dr. Thomas Jessell) diluted 1:300 and
detected with donkey anti-rabbit Alexa 555 antibodies
(Molecular Probes). Mouse anti-Isl1 39.4D5b diluted
1:300 was detected by goat anti mouse Alexa 488 (Molec-
ular Probes). Mouse anti-TNNT2 (1:500; USBiologicals)
was detected with goat anti-mouse Alexa 488; rat anti-
Endoglin (1:300; Pharmingen) was detected with the goat
anti-rat Alexa 488 antibody; all secondary antibodies were
used at a 1:500 dilution. PBS-washed slides were mounted
in Vectashield media with DAPI (Vector). Pictures were
acquired using a Magnafire camera (Olympus) with an
Olympus fluorescent microscope as previously described
[66].
Immunoprecipitation (IP)
Transient transfections were performed using an HBS ×
CaCl2 protocol essentially as described above with
HEK293 cells cultured on 10 cm plates with 9 μg of
pCS2+HA-Lhx9 combined with 9 μg pCMV5a-
Isl1α_FLAG or pCMV5a-Isl1β_FLAG or pCMV5a-
Cited2_FLAG or pCMV5a-Mab21l2_FLAG plasmid (nega-
tive control). Cells were harvested 48 hours after transfec-
tion as previously described [1]. Briefly, plates were
washed with PBS put on ice and cells were lysed directly
with a "TNN-plus" buffer [50 M Tris HCl pH7.5, 150 mM
NaCl, 0.5% Igepal (Sigma), 5 mM EDTA and a complete
Table 2: 
Gene Regions Sequence F5'♦ 3'F Sequence F5'♦ 3'R size
Lhx9_-521ChIP GAGATTTCCTTAGCTTTGCGTC ACACAAAGAAAGAGAACGAAGTGC 229
Lhx9_-4441ChIP GAGATTTCCTTAGCTTTGCGTC CTATAGAGGGAGAATGAAGAACGGTC 265
Gapdh_ChIP GTCACCTCCTGAGCGGGGCAATCTC CCCGCCTCCCGCCCTGCTTATCCAG 212
Lhx9+2X_CHIP AGGTACTATCTGCTGGCCGTAGAC CAAGGGACAGAGAAGGGACTCCGGATT 246Page 16 of 19
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supernatants were transferred to new tubes several times
to remove cell debris. IP was performed by incubating the
cleared lysates with 25 μl of Anti-HA Affinity Matrix
(Roche) for 2 h in a cold room followed by 4 washes with
TNN-plus. 1/100 of a lysate or 1/10 of an IP were analysed
by a Western blot. Proteins were detected on a Immobilon
membrane (Millipore) either with a rabbit HA antibody
(Santa Cruz) followed by an anti-rabbit HRP conjugate
(Bio-Rad; 1:3000) or directly with an anti FlagM2 peroxi-
dase Conjugate (Sigma; 1:3000).
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